Metabolic effects of adjunctive aripiprazole in clozapine-treated patients with schizophrenia.

Acta psychiatrica Scandinavica

Volumn 127, Issue 3, 2013, Pages 217-226

  Fan, X ^a   Borba, C P ^a   Copeland, P ^a   Hayden, D ^a   Freudenreich, O ^a   Goff, D C ^a   Henderson, D C ^a  

^a not available ^*

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; GLUCOSE; LOW DENSITY LIPOPROTEIN; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

ADULT; ARTICLE; BLOOD; BODY COMPOSITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; DRUG EFFECT; FEMALE; FOLLOW UP; GLUCOSE TOLERANCE TEST; HUMAN; MALE; METABOLISM; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHOTON ABSORPTIOMETRY; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA;

ABSORPTIOMETRY, PHOTON; ADULT; ANTIPSYCHOTIC AGENTS; BODY COMPOSITION; CLOZAPINE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GLUCOSE; GLUCOSE TOLERANCE TEST; HUMANS; LIPOPROTEINS, LDL; MAGNETIC RESONANCE SPECTROSCOPY; MALE; PIPERAZINES; QUINOLONES; SCHIZOPHRENIA;

EID: 85027920706     PISSN: None     EISSN: 16000447     Source Type: None    
DOI: 10.1111/acps.12009     Document Type: Article

References (0)